Compass Therapeutics, Inc. (CMPX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts CMPX Hot Sheet
Join SI Premium – FREE
Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q4 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can JetBlue still avoid bankruptcy? Analysis says yes, but it won’t be easy
- Deen Cadi CPA Expands Independent Audit & Assurance Practice to Help Growing Businesses Establish Financial Credibility and Compete Nationwide
- We are taking more action this week to ensure competition is real and not fake, or manipulated - Pulte
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
